hema.to

Seconds from raw cytometry to sound decisions

Munich, Germany · $4.0M raised

Headquarters
Munich
Employees
11–50
Business Model
B2B
Website
hema.to
Total Funding
$4.0M
Last Round
$4.0M SeedMar 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

hema.to is a Munich-based deeptech AI company developing end-to-end AI cytometry solutions for clinical diagnostics in blood cancer and immune disease. Its flagship product, CellStudio (RUO), delivers automated AI-driven population classification and reporting from flow cytometry data, removing operator variability and achieving 98.6% mean accuracy validated across 6,500+ routine results. The company's AI classification has been peer-reviewed in four publications including studies published in Blood. hema.to's platform is panel-independent, cloud-based, GDPR-validated, and EU-hosted, enabling real-time remote collaboration for hematopathology labs. Clinical partners include UPenn Medicine, Stanford Medicine, Brigham and Women's Hospital, and NIST. The company has raised approximately 3.6M EUR in seed funding and is headquartered in Munich, Germany.

Summary

hema.to is an Artificial Intelligence company based in Munich, Germany. It has raised $4.0M in total across 1 round, most recently a $4.0M Seed round in Mar 2025. Investors include LUMO Labs, Bayern Kapital and Elaia.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundMar 2025
$4.0M

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Devoted Health

Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...

Waltham, United States1001–5000Artificial Intelligence, Healthcare
Series FTotal funding$3.8BJan 2026
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Verily Life Sciences

Verily builds AI-native precision health platforms that help healthcare organizations harmonize d...

Dallas, United States1001–5000Artificial Intelligence, Healthcare
Corporate RoundTotal funding$3.0BMar 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

hema.to on Indexed.vc
<a href="https://indexed.vc/companies/hema-to"><img src="https://indexed.vc/api/badge/company/hema-to" alt="hema.to on Indexed.vc" width="260" height="76" /></a>